Skip to main content
Top
Published in: BMC Medicine 1/2015

Open Access 01-12-2015 | Commentary

Better prioritization to increase research value and decrease waste

Authors: Agnes Dechartres, Philippe Ravaud

Published in: BMC Medicine | Issue 1/2015

Login to get access

Abstract

In a recent study published in BMC Medicine, Singh Ospina and colleagues outlined the important gaps between ongoing research and research needs in the field of endocrinology. Many recommendations from clinical practice guidelines are based on a low level of evidence, thereby resulting in research gaps. Despite the publication of around 25,000 randomized controlled trials each year, ongoing research does not cover most of these gaps. In contrast, trials are planned when sufficient data are already available for decision making, which results in redundant research and exposes patients to unnecessary risks. This lack of prioritization contributes to the enormous problem of waste in research. A systematic approach to accumulate the available body of evidence is necessary to determine when we have sufficient evidence and when we have knowledge gaps, defined as research questions with no or a low level of evidence available. Systematic registration of research gaps and their prioritization may help to organize future research. Some initiatives exist, but they need to be generalized.
Literature
1.
go back to reference Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374:86–9.CrossRefPubMed Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374:86–9.CrossRefPubMed
2.
go back to reference Al-Shahi Salman R, Beller E, Kagan J, Hemminki E, Phillips RS, Savulescu J, et al. Increasing value and reducing waste in biomedical research regulation and management. Lancet. 2014;383:176–85.CrossRefPubMed Al-Shahi Salman R, Beller E, Kagan J, Hemminki E, Phillips RS, Savulescu J, et al. Increasing value and reducing waste in biomedical research regulation and management. Lancet. 2014;383:176–85.CrossRefPubMed
3.
go back to reference Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gulmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014;383:156–65.CrossRefPubMed Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gulmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014;383:156–65.CrossRefPubMed
4.
go back to reference Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gotzsche PC, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet. 2014;383:257–66.CrossRefPubMedPubMedCentral Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gotzsche PC, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet. 2014;383:257–66.CrossRefPubMedPubMedCentral
5.
go back to reference Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet. 2014;383:267–76.CrossRefPubMed Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet. 2014;383:267–76.CrossRefPubMed
6.
go back to reference Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014;383:166–75.CrossRefPubMedPubMedCentral Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014;383:166–75.CrossRefPubMedPubMedCentral
7.
go back to reference Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, et al. Biomedical research: increasing value, reducing waste. Lancet. 2014;383:101–4.CrossRefPubMed Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, et al. Biomedical research: increasing value, reducing waste. Lancet. 2014;383:101–4.CrossRefPubMed
8.
go back to reference Emdin CA, Odutayo A, Hsiao AJ, Shakir M, Hopewell S, Rahimi K, et al. Association between randomised trial evidence and global burden of disease: cross sectional study (Epidemiological Study of Randomized Trials--ESORT). BMJ. 2015;350:h117.CrossRefPubMedPubMedCentral Emdin CA, Odutayo A, Hsiao AJ, Shakir M, Hopewell S, Rahimi K, et al. Association between randomised trial evidence and global burden of disease: cross sectional study (Epidemiological Study of Randomized Trials--ESORT). BMJ. 2015;350:h117.CrossRefPubMedPubMedCentral
9.
go back to reference Corner J, Wright D, Hopkinson J, Gunaratnam Y, McDonald JW, Foster C. The research priorities of patients attending UK cancer treatment centres: findings from a modified nominal group study. Br J Cancer. 2007;96:875–81.CrossRefPubMedPubMedCentral Corner J, Wright D, Hopkinson J, Gunaratnam Y, McDonald JW, Foster C. The research priorities of patients attending UK cancer treatment centres: findings from a modified nominal group study. Br J Cancer. 2007;96:875–81.CrossRefPubMedPubMedCentral
10.
go back to reference Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 2000;355:2037–40.CrossRefPubMed Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 2000;355:2037–40.CrossRefPubMed
11.
go back to reference Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, et al. Patient-important outcomes in registered diabetes trials. JAMA. 2008;299:2543–9.CrossRefPubMed Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, et al. Patient-important outcomes in registered diabetes trials. JAMA. 2008;299:2543–9.CrossRefPubMed
12.
go back to reference Estellat C, Ravaud P. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med. 2012;172:237–44.CrossRefPubMed Estellat C, Ravaud P. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med. 2012;172:237–44.CrossRefPubMed
13.
go back to reference Ioannidis JP, Karassa FB, Druyts E, Thorlund K, Mills EJ. Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat Rev Rheumatol. 2013;9:665–73.CrossRefPubMed Ioannidis JP, Karassa FB, Druyts E, Thorlund K, Mills EJ. Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat Rev Rheumatol. 2013;9:665–73.CrossRefPubMed
14.
go back to reference Jones AP, Conroy E, Williamson PR, Clarke M, Gamble C. The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials. BMC Med Res Methodol. 2013;13:50.CrossRefPubMedPubMedCentral Jones AP, Conroy E, Williamson PR, Clarke M, Gamble C. The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials. BMC Med Res Methodol. 2013;13:50.CrossRefPubMedPubMedCentral
15.
go back to reference Singh Ospina N, Rodriguez-Gutierrez R, Brito JP, Young Jr WF, Montori VM. Is the endocrine research pipeline broken? A systematic evaluation of the Endocrine Society clinical practice guidelines and trial registration. BMC Med. 2015;13:187.CrossRefPubMedPubMedCentral Singh Ospina N, Rodriguez-Gutierrez R, Brito JP, Young Jr WF, Montori VM. Is the endocrine research pipeline broken? A systematic evaluation of the Endocrine Society clinical practice guidelines and trial registration. BMC Med. 2015;13:187.CrossRefPubMedPubMedCentral
16.
go back to reference Hazlehurst JM, Armstrong MJ, Sherlock M, Rowe IA, O’Reilly MW, Franklyn JA, et al. A comparative quality assessment of evidence-based clinical guidelines in endocrinology. Clin Endocrinol (Oxf). 2013;78:183–90.CrossRef Hazlehurst JM, Armstrong MJ, Sherlock M, Rowe IA, O’Reilly MW, Franklyn JA, et al. A comparative quality assessment of evidence-based clinical guidelines in endocrinology. Clin Endocrinol (Oxf). 2013;78:183–90.CrossRef
17.
go back to reference Lee DH, Vielemeyer O. Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines. Arch Intern Med. 2011;171:18–22.PubMed Lee DH, Vielemeyer O. Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines. Arch Intern Med. 2011;171:18–22.PubMed
18.
go back to reference Tricoci P, Allen JM, Kramer JM, Califf RM, Smith Jr SC. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301:831–41.CrossRefPubMed Tricoci P, Allen JM, Kramer JM, Califf RM, Smith Jr SC. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301:831–41.CrossRefPubMed
19.
20.
22.
go back to reference Chang SM, Carey TS, Kato EU, Guise JM, Sanders GD. Identifying research needs for improving health care. Ann Intern Med. 2012;157:439–45.CrossRefPubMed Chang SM, Carey TS, Kato EU, Guise JM, Sanders GD. Identifying research needs for improving health care. Ann Intern Med. 2012;157:439–45.CrossRefPubMed
Metadata
Title
Better prioritization to increase research value and decrease waste
Authors
Agnes Dechartres
Philippe Ravaud
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2015
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-015-0492-3

Other articles of this Issue 1/2015

BMC Medicine 1/2015 Go to the issue